The Return of the MyoKardia Team

Kardigan is a clinical-stage cardiovascular company founded by the former management team of MyoKardia, a cardiac disease biotech acquired by Bristol Myers Squibb (BMY) for $13.1 billion in 2020. CEO and co-founder Tassos Gianakakos led MyoKardia for seven years and spearheaded the FDA approval of Camzyos (mavacamten) for the treatment of hypertrophic cardiomyopathy (HCM). Co-founder Jay Edelberg and CSO Robert McDowell are also from the same team. The fact that the management team, which achieved a $13.1 billion exit, is re-challenging the same cardiovascular field is a key factor driving strong demand from institutional investors.

$400 Million Upsized IPO Successful

Kardigan (KARD) listed on Nasdaq on June 18, 2026, offering 25 million shares at $16 per share (the upper end of the $14 to $16 range), raising a total of $400 million. The offering was upsized from the initial plan of 23.3 million shares, and the underwriters were granted an additional 3.75 million shares (greenshoe option), potentially increasing the total amount raised to $4.6 billion. The market capitalization at the time of listing is approximately $1.43 billion, and the company had already secured approximately $600 million in a pre-IPO private round (including a $254 million Series B), bringing the total available capital to $1 billion.

Three Main Pipeline Products: Targeting Indications with No Approved Drugs

The lead drug, danicamtiv, is a cardiac myosin activator licensed from BMS, and a Phase 2b/3 KINSHIP-DCM trial is underway for the treatment of genetic dilated cardiomyopathy (DCM), an indication with no approved drugs. The second drug, ataciguat, is a soluble guanylate cyclase (sGC) activator acquired from Sanofi and Mayo Clinic, and a pivotal Phase 3 KATALYST-AV trial (1,400 patients) has begun for the treatment of calcific aortic valve stenosis (CAVS), based on positive Phase 2 results. The third drug, tonlamarsen, is an antisense oligonucleotide (ASO) co-developed with Ionis Pharmaceuticals (IONS), and is in Phase 2b for the treatment of acute severe hypertension (ASH). All three drugs are expected to have key data readouts in the first and second halves of 2027.

2026: A Wave of Large Biotech IPOs

Including Kardigan, there are four biotechs that have achieved IPOs of $400 million or more in 2026: Generate:Biomedicines (GENB, $400 million), Kailera Therapeutics (KAIL, $625 million – the largest biotech IPO in Nasdaq history), and Eikon Therapeutics. This is the highest number of large biotech IPOs since 2021. Next-generation therapeutic areas such as obesity (Kailera), AI-based protein therapeutics (Generate), and cardiovascular precision medicine (Kardigan) are attracting significant institutional funding, and the median IPO amount in 2026 is approximately $302 million, a significant increase from the previous year.